Voyager Therapeutics Extends Cash Runway to 2028

Voyager Therapeutics Inc. ( (VYGR) ) has released its Q2 earnings. Here is a breakdown of the information Voyager Therapeutics Inc. presented to its investors.

Voyager Therapeutics, Inc. is a biotechnology company focused on using genetic approaches to treat neurological diseases, with a notable presence in the Alzheimer’s disease research sector. In its second quarter 2025 earnings report, Voyager Therapeutics highlighted its extended cash runway into 2028, the addition of a new APOE program to its Alzheimer’s disease pipeline, and the potential for significant milestone payments from its partnered programs. Key financial metrics showed a decrease in collaboration revenue to $5.2 million from $29.6 million year-over-year, while research and development expenses slightly decreased, and the company reported a net loss of $33.4 million for the quarter. Despite the financial challenges, Voyager’s strategic focus remains on advancing its clinical programs, with expectations to have four programs in the clinic by next year. Looking ahead, Voyager Therapeutics is positioned to reach multiple clinical milestones, supported by its strong cash position and strategic partnerships, as it continues to pursue advancements in neurotherapeutics.